SEARCH

SEARCH BY CITATION

References

  • 1
    Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 1939.
  • 2
    Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 68590.
  • 3
    Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17: 56476.
  • 4
    Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis – a randomised clinical trial. J Hepatol 2006; 44: 78490.
  • 5
    Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47: 27783.
  • 6
    Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 84550.
  • 7
    Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004; 24: 21732.
  • 8
    Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 4454.
  • 9
    Tao N, Sussman S, Nieto J, Tsukamoto H, Yuan JM. Demographic characteristics of hospitalized patients with alcoholic liver disease and pancreatitis in Los Angeles county. Alcohol Clin Exp Res 2003; 27: 1798804.
  • 10
    Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 10811.
  • 11
    Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 10259.
  • 12
    Orrego H, Blake JE, Blendis LM, Kapur BM, Israel Y. Reliability of assessment of alcohol intake based on personal interviews in a liver clinic. Lancet 1979; 2: 13546.
  • 13
    Han SH, Rice S, Cohen SM, Reynolds TB, Fong TL. Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol 2002; 34: 5737.
  • 14
    Cohen JA, Kaplan MM. The SGOT/SGPT ratio—an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24: 8358.
  • 15
    Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 101822.
    Direct Link:
  • 16
    Jamal MM, Morgan TR. Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003; 17: 64962.
  • 17
    Mendenhall CL, Moritz T, Chedid A, et al. Relevance of anti-HCV reactivity in patients with alcoholic hepatitis. VA cooperative Study Group #275. Gastroenterol Jpn 1993; 28: 95100.
  • 18
    Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51: 163743.
  • 19
    Sumino Y, Kravetz D, Kanel GC, McHutchison JG, Reynolds TB. Ultrasonographic diagnosis of acute alcoholic hepatitis ‘pseudoparallel channel sign’ of intrahepatic artery dilatation. Gastroenterology 1993; 105: 147782.
  • 20
    Levin DM, Baker AL, Riddell RH, Rochman H, Boyer JL. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med 1979; 66: 42934.
  • 21
    Mathurin P, Poynard T, Ramond MJ, et al. Interet de la biopsie hepatique pour la selection des sujets suspects d’hepatitis alcoolique aigue. Journees francophones d’hepatologie et de pathologies digestives. Gastroenterol Clin Biol 1992; 16: 231A.
  • 22
    Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tisuue samplings with the procedure. Gastroenterology 1982; 83: 33840.
  • 23
    Bull HJ, Gilmore IT, Bradley RD, Marigold JH, Thompson RP. Experience with transjugular liver biopsy. Gut 1983; 24: 105760.
  • 24
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 101744.
  • 25
    Chedid A, Mendenhall CL, Moritz TE, et al. Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology 1993; 105: 25466.
  • 26
    Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liv Dis 2005; 9: 3753.
  • 27
    French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. VA Cooperative Study Group 119. Semin Liv Dis 1993; 13: 15469.
  • 28
    Spahr L, Rubbia-Brandt L, Pugin J, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001; 35: 5829.
  • 29
    Wells JT, Said A, Agni R, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl 2007; 13: 172835.
  • 30
    Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26: 1418.
  • 31
    Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 46470.
  • 32
    Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797805.
  • 33
    Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 3538.
  • 34
    Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 7006.
  • 35
    International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53: 1556.
  • 36
    Caldwell S, Shah N. The prothrombin time-derived international normalized ratio: great for Warfarin, fair for prognosis and bad for liver-bleeding risk. Liver Int 2008; 28: 13257.
  • 37
    Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost 2008; 6: 2438.
  • 38
    Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 11749.
  • 39
    Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 17436.
  • 40
    Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971; 56: 51525.
  • 41
    Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec’s cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 40620.
  • 42
    Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 200317.
  • 43
    Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006; 40: 38393.
  • 44
    Chick J, Lehert P, Landron F, Plinius Maior Society. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 2003; 17: 397402.
  • 45
    Mason BJ. Acamprosate. Recent Dev Alcohol 2003; 16: 20315.
  • 46
    Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 5048.
  • 47
    Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 2004; 28: 151723.
  • 48
    Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 191522.
  • 49
    Niemela O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990; 98: 16129.
  • 50
    Reynolds TB, Geller HM, Kuzma OT, Redeker AG. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960; 263: 7349.
  • 51
    Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76: 21122.
  • 52
    Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986; 43: 2138.
  • 53
    DiCecco SR, Francisco-Ziller N. Nutrition in alcoholic liver disease. Nutr Clin Pract 2006; 21: 24554.
  • 54
    Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis 2004; 24: 289304.
  • 55
    Nielsen K, Kondrup J, Martinsen L, Stilling B, Wikman B. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. Br J Nutr 1993; 69: 66579.
  • 56
    Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology 1988; 8: 16059.
  • 57
    Kiilerich S, Dietrichson O, Loud FB, et al. Zinc depletion in alcoholic liver diseases. Scand J Gastroenterol 1980; 15: 3637.
  • 58
    Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 2005; 26: 391404.
  • 59
    Henkel AS, Buchman AL. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 2029.
  • 60
    Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003; 18: 35773.
  • 61
    Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 3642.
  • 62
    Plauth M, Cabre E, Riggio O, et al. ESPEN Guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25: 28594.
  • 63
    Morgan TR, Moritz TE, Mendenhall CL, Haas R. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. VA Cooperative Study Group #275. J Am Coll Nutr 1995; 14: 1528.
  • 64
    Schulz GJ, Campos AC, Coelho JC. The role of nutrition in hepatic encephalopathy. Curr Opin Clin Nutr Metab Care 2008; 11: 27580.
  • 65
    McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 202236.
    Direct Link:
  • 66
    Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 1138.
  • 67
    Daures JP, Peray P, Bories P, et al. [Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis]. Gastroenterol Clin Biol 1991; 15: 2238.
  • 68
    Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials Ann Intern Med 1990; 113: 299307.
  • 69
    Reynolds TB, Benhamou J, Blake JE, Naccarato R, Orrego H. Treatment of alcoholic hepatitis. Gastroenterol Int 1989; 2: 20816.
  • 70
    Helman RA, Temko MH, NYE SW, Fallon HJ. Alcoholic hepatitis: natural history and evaluation of prednisolone therapy. Ann Intern Med 1971; 74: 31121.
  • 71
    Porter HP, Simon FR, Pope CE II, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis: a double-blind drug trial. N Eng J Med 1971; 284: 13505.
  • 72
    Campra JL, Hamlin EM Jr, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis: report of a controlled trial. Ann Intern Med 1973; 79: 62531.
  • 73
    Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective double-blind randomized trial. Am J Dig Dis 1977; 22: 47784.
  • 74
    Mendenhall CL, Goldberg S. Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology 1977; 72: 1100.
  • 75
    Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978; 74: 16973.
  • 76
    Galambos JT. Unpublished trial. Quoted by Conn HO. Steroid treatment of alcoholic hepatitis. The yeas and the nays. Gastroenterology 1978; 74: 31922.
  • 77
    Shumaker JB, Resnick RH, Galambos JT, et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69: 4439.
  • 78
    Depew W, Boyer T, Omata M, et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78: 5249.
  • 79
    Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 759.
  • 80
    Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 146470.
  • 81
    Bories P, Guedj JY, Mirouze D, et al. Prednisolone treatment of alcoholic hepatitis: forty-five cases. Presse Med 1987; 16: 76972.
  • 82
    Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 50712.
  • 83
    Richardet JP, Dehoux M, Mal F, et al. Influence of corticosteroids (CS) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (AH): results of a randomized study. J Hepatol 1993; 18: S75.
  • 84
    Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 116778.
  • 85
    Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 4807.
  • 86
    Mathurin P, O’Grady J, Carithers RL Jr, et al. Corticosteroids improve 28-day survival in patients with severe alcoholic hepatitis: individual data analysis of the last 5 randomized controlled trials [Abstract]. Hepatology 2008; 48(Suppl.1): 635A.
  • 87
    Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 13639.
  • 88
    Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 134854.
  • 89
    Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 46570.
  • 90
    Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 12306.
  • 91
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 163748.
  • 92
    Sidhu S, Singla M, Bhatia K. Pentoxfylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial [Abstract]. Hepatology 2006; 44(Suppl. 1): 373A.
  • 93
    Macavoy NC, Forrest E, Hayes PC. The influence of Pentoxfylline on mortality in alcoholic hepatitis and benefit of the Glascow Alcoholic Hepatitis Score (GAHS) [Abstract]. Hepatology 2005; 42(Suppl.1): 492A.
  • 94
    Louvet A, Diaz E, Texier F, et al. Evaluation of Pentoxfylline in patients with severe alcoholic hepatitis non responders to corticosteroids: a pilot controlled study [Abstract]. Hepatology 2005; 42(Suppl.1): 493A.
  • 95
    Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized, placebo-controlled, double-blind trial [Abstract]. Hepatology 2007; 46(Suppl. 1): 249A.
  • 96
    McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287: G497502.
  • 97
    Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 44855.
  • 98
    Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003; 52: 11827.
  • 99
    Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 41925.
  • 100
    Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 13907.
  • 101
    Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 195360.
  • 102
    Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev (Online) 2006; 2: CD003328.
  • 103
    Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol 1998; 36: 27785.
  • 104
    Israel Y, Orrego H. Propylthiouracil in the treatment of alcoholic liver disease. In: LieberCS, ed. Biological Approach to Alcoholism. Washington, DC: Department of Health and Human Services, 1983: 47482.
  • 105
    Israel Y, Kalant H, Orrego H, Khanna JM, Videla L, Phillips JM. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci U S A 1975; 72: 113741.
  • 106
    Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987; 317: 14217.
  • 107
    Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease – a Cochrane Hepato-Biliary Group Review. Liver 2001; 21: 398404.
  • 108
    Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev (Online) 2005; 4: CD002800.
  • 109
    Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev (Online) 2006; 4: CD003045.
  • 110
    Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100: 258391.
    Direct Link:
  • 111
    Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 126.
  • 112
    Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007; 13: 197205.
  • 113
    Bjornsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol 2005; 40: 20616.
  • 114
    DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006; 12: 81320.
  • 115
    Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003; 38: 62934.
  • 116
    Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997; 3: 2206.
    Direct Link: